| 1.1 Improvement in vertigo frequency |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1.1 6 to ≤ 12 months |
1 |
70 |
Risk Ratio (M‐H, Random, 95% CI) |
1.50 [0.98, 2.29] |
| 1.1.2 ≥ 12 months |
1 |
62 |
Risk Ratio (M‐H, Random, 95% CI) |
1.11 [0.93, 1.32] |
| 1.2 Improvement in vertigo frequency: sensitivity analysis for complete/substantial improvement |
1 |
|
Peto Odds Ratio (Peto, Fixed, 95% CI) |
Subtotals only |
| 1.2.1 6 to ≤ 12 months |
1 |
10 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
13.08 [1.01, 170.31] |
| 1.3 Improvement in vertigo frequency: sensitivity analysis for complete/substantial improvement |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.3.1 ≥ 12 months |
1 |
62 |
Risk Ratio (M‐H, Random, 95% CI) |
1.37 [1.04, 1.81] |
| 1.4 Change in vertigo global score at 3 to 6 months |
1 |
34 |
Mean Difference (IV, Random, 95% CI) |
0.70 [‐6.67, 8.07] |
| 1.5 Change in vertigo frequency |
3 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.5.1 3 to 6 months |
2 |
117 |
Mean Difference (IV, Random, 95% CI) |
‐1.90 [‐3.05, ‐0.74] |
| 1.5.2 6 to ≤ 12 months |
1 |
214 |
Mean Difference (IV, Random, 95% CI) |
0.63 [‐4.07, 5.33] |
| 1.6 Serious adverse events |
1 |
220 |
Risk Ratio (M‐H, Random, 95% CI) |
1.20 [0.63, 2.29] |
| 1.7 Disease‐specific health‐related quality of life at 6 to ≤ 12 months |
1 |
170 |
Mean Difference (IV, Random, 95% CI) |
0.06 [‐0.17, 0.29] |
| 1.8 Disease‐specific health‐related quality of life at > 12 months |
1 |
62 |
Risk Ratio (M‐H, Random, 95% CI) |
1.34 [1.07, 1.69] |
| 1.9 Change in hearing: continuous data only |
3 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.9.1 3 to < 6 months |
1 |
35 |
Mean Difference (IV, Random, 95% CI) |
10.10 [‐1.13, 21.33] |
| 1.9.2 6 to ≤ 12 months |
1 |
113 |
Mean Difference (IV, Random, 95% CI) |
2.64 [‐1.66, 6.94] |
| 1.9.3 > 12 months |
1 |
62 |
Mean Difference (IV, Random, 95% CI) |
1.40 [‐7.10, 9.90] |
| 1.10 Change in hearing: dichotomous data only |
2 |
|
Peto Odds Ratio (Peto, Fixed, 95% CI) |
Subtotals only |
| 1.10.1 6 to ≤ 12 months |
2 |
82 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
3.14 [1.28, 7.66] |
| 1.11 Change in tinnitus |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.11.1 6 to ≤ 12 months |
1 |
168 |
Mean Difference (IV, Random, 95% CI) |
‐0.06 [‐1.52, 1.39] |
| 1.11.2 ≥ 12 months |
1 |
62 |
Mean Difference (IV, Random, 95% CI) |
0.90 [‐5.55, 7.35] |
| 1.12 Other adverse effects |
4 |
|
Peto Odds Ratio (Peto, Fixed, 95% CI) |
Subtotals only |
| 1.12.1 Headache |
4 |
374 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
1.16 [0.69, 1.95] |
| 1.12.2 Gastrointestinal disturbance |
4 |
372 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
1.08 [0.65, 1.78] |
| 1.12.3 Dry mouth |
2 |
301 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.30 [0.05, 1.95] |
| 1.13 Other adverse effects |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.13.1 Sleep disturbance |
2 |
255 |
Risk Ratio (M‐H, Random, 95% CI) |
1.43 [0.47, 4.38] |
